FEASIBILITY STUDY OF A MODULAR CONTROL TO RANGE SYSTEM IN T1DM

T1DM 测距系统模块化控制的可行性研究

• 批准号: 8167201
• 负责人: MARC D BRETON
• 金额: $ 3.74万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-01 至 2013-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167201
• 关键词: Artificial Pancreas; Computer Retrieval of Information on Scientific Projects Database; Environment; Event; Exercise; Feasibility Studies; Frequencies; Funding; Glucose; Grant; Health; Hospitals; Hyperglycemia; Hypoglycemia; Injection of therapeutic agent; Institution; Insulin; Metabolic; Monitor; Patient Monitoring; Patients; Performance; Protocols documentation; Regulation; Research; Research Personnel; Resources; Sleep; Source; System; Testing; Time; Toxic effect; United States National Institutes of Health; Variant; base; blood glucose regulation; design; prevent; subcutaneous

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. As artificial pancreas systems are tested in hospital settings and eventually in field conditions, it becomes apparent that such systems suffer from ample glucose excursions, both in hypoglycemia and hyperglycemia. The need for supervisory systems that prevent such large glucose variation rise from the incapacity of modern controllers to properly adapt and react to very high and/or very low glucose, and the resulting qualitative metabolic changes (e.g. counter-regulation and gluco-toxicity). Such supervisory systems, called controllers to range, are not aiming at perfect glucose control (i.e. glucose variations comparable to health) but at mitigating large glucose deviations, keeping the patient safe and create the environment for more precise control strategies to function optimally. This protocol is designed to demonstrate the feasibility in a GCRC setting of such a supervisory system during different metabolic conditions, such as meals, mild exercise and sleep. Our system is based on continuous monitoring and subcutaneous insulin injections, and monitors the patient's regular treatment, i.e. unless an error in treatment is detected (glucose going low or high) the system will stay inactive. Performances of the system will be assessed using frequency of hypoglycemic events and amount of time spent in a wide glucose target range

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 随着人工胰腺系统在医院环境中以及最终在野外条件下进行测试，很明显，这种系统在低血糖和高血糖两种情况下都会出现足够的血糖漂移。由于现代控制器不能正确适应和反应极高和/或极低的血糖，以及由此导致的质量代谢变化(如逆调节和葡萄糖毒性)，因此需要防止如此大的血糖变化的监控系统。这种被称为范围控制器的监控系统的目标不是完美的血糖控制(即与健康相当的血糖变化)，而是减轻较大的血糖偏差，确保患者的安全，并为更精确的控制策略创造最佳运行的环境。该方案旨在证明在GCRC环境下，在不同的代谢条件下，如进餐、轻度运动和睡眠，这种监测系统的可行性。我们的系统基于连续监测和皮下注射胰岛素，并监测患者的常规治疗，即除非检测到治疗中的错误(血糖变低或升高)，否则系统将保持不活动。该系统的性能将通过低血糖事件的频率和在广泛的血糖目标范围内花费的时间来评估